
Tarlatamab Shows Significant OS Improvement in Post-Platinum SCLC
Tarlatamab-dlle (Imdelltra) showed a statistically significant and clinically meaningful improvement in overall survival (OS) vs local standard-of-care (SOC) chemotherapy when used for the treatment of patients with small cell lung cancer (SCLC) who …